SynthesisBlood2024

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma.

Ola Landgren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.